Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SARS CoV-2 mRNA vaccine platform in healthy Thai adolescents
TCTR20210917004Phase 2Completed
- Sponsor
- National Vaccine Institute
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of LVRNA021 in coronavirus disease 2019 (COVID-19), sponsored by National Vaccine Institute. Started Sep 2021; status: completed.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210917004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210917004.